Abstract: A dose indicating device constructed for use with an inhalator is disclosed. The inhalator contains multiple doses of a medicament and has an operational portion that includes a dosing unit defining an inhalation channel, and a maneuvering element. The maneuvering element loads a dose of the medicament to the dosing unit and provides the dose in a position in the inhalation channel for inhalation.

Abstract: New aqueous formulations of, and the paediatric use of, bambuterol, and of its pharmaceutically acceptable salts, are described.

Abstract: The invention relates to a pharmaceutical composition for topical administration comprising a combination of foscarnet and an antiinflammatory glucocorticoid, in admixture with a carrier based on galactolipids and a polar solvent. The pharmaceutical composition can be used in a prophylactic and/or curative treatment of herpesvirus infections in mammals including man.The invention also relates to the use of said pharmaceutical composition in the manufacture of a medicament for said prophylactic or curative treatment.

Abstract: A catheter package (10; 110; 210) comprising a catheter (1; 101; 201) positioned within an inner container (2; 102; 202) permeable to a sterilizing agent, for example an ethylene oxide gas. An outer container (3; 103; 203) which prevents access of moisture to the interior thereof encloses the inner container and catheter assembly. Two or more catheters may be stored in individual inner containers within the outer container.

Abstract: There are provided novel compounds of formula (I) ##STR1## including their 3,4-dihydropyrimidine tautomer form, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X and n are as defined in the specification, and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are antagonists of N-type neuronal calcium channels useful in the treatment of cerebrovascular ischaemia and pain.

Abstract: A compound of formula ##STR1## X is O or S; Y is O or S; G and D are independently nitrogen or carbon with the proviso that no more than one of G, D, or E is nitrogen; E is N or C--R.sub.4 ; R.sub.1 is hydrogen or methyl; R.sub.2 is hydrogen or fluoro; R.sub.3 is hydrogen, halogen, C.sub.1 to C.sub.3 alkyl, --OR.sub.5, --CN, --CONH.sub.2, --CO.sub.2 R.sub.5, --NR .sub.5 R.sub.6 or phenyl optionally substituted with one to three of the following substituents: halogen, C.sub.1 to C.sub.3 alkyl, --NO.sub.2, --CN, or --OCH.sub.3 ; R.sub.4 is hydrogen, halogen, C.sub.1 to C.sub.3 alkyl, --OR.sub.5, --CN, --CONH.sub.2, --CO.sub.2 R.sub.5, --NR.sub.5 R.sub.6 or phenyl optionally substituted with one to three of the following substituents: halogen, C.sub.1 to C.sub.3 alkyl, --NO.sub.2, --CN, or --OCH.sub.3 ;or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.4 may together represent a fused phenyl ring optionally substituted with one or two of the following substituents: halogen, C.sub.1 to C.sub.3 alkyl, --NO.sub.

Abstract: There are provided new compounds of formula I: ##STR1## wherein R represents hydrogen or methyl; andn represents 1 or 2;or a pharmaceutically acceptable acid addition salt thereof, together with processes for preparing them, compositions containing them and their use in therapy. Compounds of formula I are expected to be useful in the treatment of psychotic disorders, intellectual impairment disorders and anxiety.

Abstract: There is provided amino acid derivative formula I, ##STR1## wherein p, q, R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Abstract: A proliposome powder, said powder comprising in a single phase discrete particles of a biologically active component together with a lipid or mixture of lipids having a phase transition temperature of below 37.degree. C. and a process for the manufacture of a proliposome powder for inhalation.

Abstract: Compounds of the formula I ##STR1## a process for their preparation, their use in the treatment of autoimmune disorders as well as new intermediates for their preparation.

Abstract: The present invention relates to a thread or oriented macroroughness for bone implants, particularly threaded dental implants, a section of said thread or roughness (i.e. the profile) comprising two flanks, a top radius R at the apex formed by the intersection of said two flanks, a bottom radius r formed at the bottom of the groove between two adjacent threads or roughnesses, said flanks forming an angle v with a plane which is perpendicular to a cross-section of said thread or roughness and perpendicular to the surface of the implant body, said profile further having a height D. According to the invention the dimensions of the thread or roughness are subject to the following restrictions: for 10.degree..ltoreq.v<35.degree., R is greater than 0.4.times.D and that, for 35.degree..ltoreq.v<55.degree., R is greater than 0.2.times.D. In a preferred embodiment the restrictions are: for 0.05 mm.ltoreq.D.ltoreq.0.5 mm and 35.ltoreq.v.ltoreq.55.degree., the top radius R is larger than 0.2.times.

Abstract: Use of bambuterol or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation with lipid lowering effect.

Abstract: The present invention relates a novel class of biologically active compounds, to processes for their production and to their use in therapy. More particularly the invention provides immunogenic conjugates useful for generating T cell immunity against tumor-associated carbohydrate structures or against carbohydrate structures expressed on infectious agents and/or infected host cells. The said immunogenic conjugate comprises,(i) a peptide component capable of binding a MHC class I molecule; and (ii) a carbohydrate component having the immunogenic specificity of said carbohydrate structure.

Abstract: The present invention relates to a device for determining the correct lengths of standardized components of a dental implant system in situ in the oral cavity. The device comprises an elongate gauge body being provided with circumferential dark bands located at predetermined distances from each other and having predetermined widths, the areas between said darker bands having a pronouncedly lighter color, each boundary line between lighter and darker bands corresponding to one specific, standardized component.

Abstract: The present invention relates to recombinant vectors which are useful for direct selection of colonies harboring recombinant plasmids, on basis of the loss of expression of a gene coding for an AsiA polypeptide from E. coli bacteriophage T4, the expression of which would normally have resulted in toxicity to the bacterial host. The invention also relates to host cells harboring the vectors, as well as to methods utilizing the vectors, for the selection of nucleic acid clones.

Abstract: The present invention relates to methods and compositions useful for treating and preventing conditions in which inhibition of nitric oxide synthetase is beneficial. These conditions include stroke, schizophrenia, anxiety, and pain.

Abstract: A dry powder composition comprising one or more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.